[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1708991T1 - Derivati sulfonamida za zdravljenje bolezni - Google Patents

Derivati sulfonamida za zdravljenje bolezni

Info

Publication number
SI1708991T1
SI1708991T1 SI200530103T SI200530103T SI1708991T1 SI 1708991 T1 SI1708991 T1 SI 1708991T1 SI 200530103 T SI200530103 T SI 200530103T SI 200530103 T SI200530103 T SI 200530103T SI 1708991 T1 SI1708991 T1 SI 1708991T1
Authority
SI
Slovenia
Prior art keywords
diseases
treatment
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
SI200530103T
Other languages
English (en)
Inventor
Alan D Pfizer Global Res Brown
Mark E Pfizer Global R Bunnage
Paul A Pfizer Global R Glossop
Kim Pfizer Global Resear James
Charlotte A L Pfizer Glob Lane
Russell A Pfizer Gl Lewthwaite
Ian B Pfizer Global Rese Moses
David A Pfizer Global Re Price
Nicholas M Pfizer Glob Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1708991(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of SI1708991T1 publication Critical patent/SI1708991T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI200530103T 2004-01-22 2005-01-12 Derivati sulfonamida za zdravljenje bolezni SI1708991T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
EP05702252A EP1708991B1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
SI1708991T1 true SI1708991T1 (sl) 2008-02-29

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530103T SI1708991T1 (sl) 2004-01-22 2005-01-12 Derivati sulfonamida za zdravljenje bolezni

Country Status (30)

Country Link
US (4) US7244766B2 (sl)
EP (1) EP1708991B1 (sl)
JP (1) JP4020954B2 (sl)
AP (1) AP2359A (sl)
AR (1) AR047509A1 (sl)
AT (1) ATE375977T1 (sl)
AU (1) AU2005214153B2 (sl)
BR (1) BRPI0507085A (sl)
CA (1) CA2553789C (sl)
DE (1) DE602005002930T2 (sl)
DK (1) DK1708991T3 (sl)
DO (1) DOP2005000006A (sl)
EA (1) EA011167B1 (sl)
ES (1) ES2293530T3 (sl)
GE (1) GEP20094781B (sl)
MY (1) MY143390A (sl)
NL (1) NL1028087C2 (sl)
NO (1) NO20062983L (sl)
NZ (1) NZ548318A (sl)
OA (1) OA13362A (sl)
PA (1) PA8622001A1 (sl)
PE (1) PE20051136A1 (sl)
PL (1) PL1708991T3 (sl)
PT (1) PT1708991E (sl)
RS (1) RS50561B (sl)
SI (1) SI1708991T1 (sl)
TW (1) TWI341831B (sl)
UA (1) UA84048C2 (sl)
UY (1) UY28721A1 (sl)
WO (1) WO2005080313A2 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005002930T2 (de) * 2004-01-22 2008-07-24 Pfizer Inc. Sulfonamidderivate zur behandlung von krankheiten
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
EP1907356A2 (en) * 2005-07-18 2008-04-09 Pfizer Limited Process for the preparation of sulfonamide derivatives
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
CN102272104B (zh) 2008-12-30 2014-07-09 帕尔马根治疗(炎症)有限公司 用于治疗呼吸疾病的磺酰胺化合物
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
EP4171525A1 (en) 2020-06-26 2023-05-03 Mylan Pharma UK Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU745081B2 (en) * 1997-06-27 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
DE10244972B4 (de) * 2002-03-26 2013-02-28 The Japan Steel Works, Ltd. Wärmefester Stahl und Verfahren zur Herstellung desselben
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
DE602005002930T2 (de) * 2004-01-22 2008-07-24 Pfizer Inc. Sulfonamidderivate zur behandlung von krankheiten

Also Published As

Publication number Publication date
EP1708991B1 (en) 2007-10-17
NO20062983L (no) 2006-07-24
PT1708991E (pt) 2007-12-14
JP2007518789A (ja) 2007-07-12
DK1708991T3 (da) 2008-01-14
WO2005080313A9 (en) 2006-08-31
US20050182091A1 (en) 2005-08-18
AP2006003669A0 (en) 2006-06-30
US20100273758A1 (en) 2010-10-28
UA84048C2 (ru) 2008-09-10
DOP2005000006A (es) 2005-07-31
TWI341831B (en) 2011-05-11
WO2005080313A3 (en) 2005-12-01
DE602005002930T2 (de) 2008-07-24
EA011167B1 (ru) 2009-02-27
EP1708991A2 (en) 2006-10-11
ES2293530T3 (es) 2008-03-16
PE20051136A1 (es) 2006-02-18
WO2005080313A2 (en) 2005-09-01
NL1028087C2 (nl) 2006-05-09
TW200530165A (en) 2005-09-16
AR047509A1 (es) 2006-01-25
DE602005002930D1 (de) 2007-11-29
CA2553789C (en) 2011-07-19
PL1708991T3 (pl) 2008-02-29
ATE375977T1 (de) 2007-11-15
UY28721A1 (es) 2005-08-31
CA2553789A1 (en) 2005-09-01
EA200601223A1 (ru) 2006-12-29
GEP20094781B (en) 2009-09-25
NL1028087A1 (nl) 2005-07-25
US7528170B2 (en) 2009-05-05
US8013019B2 (en) 2011-09-06
AP2359A (en) 2012-01-30
RS50561B (sr) 2010-05-07
US20080267970A1 (en) 2008-10-30
AU2005214153B2 (en) 2008-09-18
OA13362A (en) 2007-04-13
MY143390A (en) 2011-05-13
JP4020954B2 (ja) 2007-12-12
US7244766B2 (en) 2007-07-17
US20090197912A1 (en) 2009-08-06
BRPI0507085A (pt) 2007-06-19
PA8622001A1 (es) 2005-08-30
NZ548318A (en) 2009-03-31
AU2005214153A1 (en) 2005-09-01
US7767715B2 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
IL176629A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL181049A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
GB0523961D0 (en) The treatment of ophthalmic diseases
GB0400802D0 (en) Compounds for the treatment of disease
ZA200606780B (en) Compounds for the treatment of diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
HK1096379A1 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0408297D0 (en) Indole derivatives for the treatment of diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0523962D0 (en) The treatment of ophthalmic diseases
GB0523965D0 (en) The treatment of ophthalmic diseases
GB0415352D0 (en) Compounds for the treatment of disease